The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Aromatase inhibitors for breast cancer: lessons from the laboratory
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Estradiol Rapidly Activates Akt via the ErbB2 Signaling Pathway
Stoica, G. E., Franke, T. F., Wellstein, A., Czubayko, F., List, H.-J., Reiter, R., Morgan, E., Martin, M. B., & Stoica, A. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0330 · Cited by 118
RetractedTamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793
Functional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
The human estrogen receptor has two independent nonacidic transcriptional activation functions
Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., & Chambon, P. (1989) · Cell · doi:10.1016/0092-8674(89)90031-7 · Cited by 1,048
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Self-citationEndocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Reid, G., Hübner, M. R., Métivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., & Gannon, F. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00090-x · Cited by 732
Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013128213451 · Cited by 713
Webb, P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.4.443 · Cited by 693
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years
Peto, R., Boreham, J., Clarke, M., Davies, C., & Beral, V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02277-7 · Cited by 648
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Self-citationBonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Proximal Events in Signaling by Plasma Membrane Estrogen Receptors
Razandi, M., Pedram, A., Park, S. T., & Levin, E. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205692200 · Cited by 473
Pasqualini, J. R. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.4.1460 · Cited by 433
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne, C. K., Hobbs, K., & Clark, G. M. (1985) · PubMed · Cited by 402
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 367
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Harada, N., Utsumi, T., & Takagi, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11312 · Cited by 361
Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor
Levin, E. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0368 · Cited by 329
Means, G. D., Mahendroo, M. S., Corbin, C. J., Mathis, J. M., Powell, F. E., Mendelson, C. R., & Simpson, E. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47313-4 · Cited by 318
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.10.2918 · Cited by 307
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Self-citationMartin, L.-A., Farmer, I., Johnston, S. R. D., Ali, S., Marshall, C., & Dowsett, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305226200 · Cited by 295
Self-citationThe importance of local synthesis of estrogen within the breast
Miller, W. R., & O'Neill, J. (1987) · Steroids · doi:10.1016/0039-128x(87)90037-7 · Cited by 280
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 278
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
Speirs, V., Malone, C. M., Walton, D. S., Kerin, M. J., & Atkin, S. L. (1999) · PubMed · Cited by 267
McClelland, R. A., Barrow, D., Madden, T., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M. W., & Nicholson, R. I. (2001) · Endocrinology · doi:10.1210/en.142.7.2776 · Cited by 258
Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V., & DeGregorio, M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1477 · Cited by 235
Paridaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, L., Cufer, T., Duchateau, L., Hamilton, A., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg362 · Cited by 230
Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo
Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211
Heshmati, H. M., Khosla, S., Robins, S. P., O'Fallon, W. M., Melton, L. J., & Riggs, B. L. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.172 · Cited by 207
Girault, I., Lerebours, F., Amarir, S., Tozlu, S., Tubiana-Hulin, M., Lidereau, R., & Bièche, I. (2003) · PubMed · Cited by 193
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
Karnik, P. S., Kulkarni, S., Liu, X.-P., Budd, G. T., & Bukowski, R. M. (1994) · PubMed · Cited by 192
Johnston, S. R. D., Lü, B., Scott, G. K., Kushner, P. J., Smith, I. E., Dowsett, M., & Benz, C. C. (1999) · PubMed · Cited by 172
Self-citationShim, W.-S., Conaway, M., Masamura, S., Yue, W., Wang, J.-P., Kumar, R., & Santen, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.1.7270 · Cited by 169
Haynes, B. P., Dowsett, M., Miller, W. R., Dixon, J. M., & Bhatnagar, A. S. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00384-4 · Cited by 165
Self-citationSelective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00297-x · Cited by 156
Schrey, M., & Patel, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.523 · Cited by 155
Wolf, D. M., & Jordan, V. C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689683 · Cited by 155
Chan, C. M. W., Martin, L., Johnston, S. R. D., Ali, S., & Dowsett, M. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00074-2 · Cited by 149
Self-citationHarper-Wynne, C. L., Ross, G., Sacks, N. P. M., Salter, J., Nasiri, N., Iqbal, J., A’Hern, R., & Dowsett, M. (2002) · PubMed · Cited by 138
Self-citationMcDonnell, D. P., Connor, C. E., Wijayaratne, A., Chang, C.-Y., & Norris, J. D. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.295 · Cited by 130
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Selective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00183-5 · Cited by 124
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy
Simpson, E. R., & Dowsett, M. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.317 · Cited by 112
Self-citationGoss, P. E., Winer, E. P., Tannock, I. F., & Grou, L. H. S. O. B. O. T. N. A. V. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.52 · Cited by 111
Masi, L., Becherini, L., Gennari, L., Amedei, A., Colli, E., Falchetti, A., Farci, M., Silvestri, S., Gonnelli, S., & Brandi, M. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7450 · Cited by 109
Jeng, M., Yue, W., Eischeid, A. C., Wang, J., & Santen, R. J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006406030612 · Cited by 99
Thurlimann, B. J. K., Beretta, K., Bacchi, M., Castiglione‐Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M. F., & Löhnert, T. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010635 · Cited by 95
Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study.
Kao, Y., Cẩm, L. L. P., Laughton, C. A., Zhou, D., & Chen, S. (1996) · PubMed · Cited by 93
Smith, I. E., Harris, A. L., Morgan, M., Gazet, J. C., & McKinna, J. A. (1982) · PubMed · Cited by 92
Harper-Wynne, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1026 · Cited by 90
Dumont, J. A., Bitonti, A. J., Wallace, C. D., et al. (1996) · PubMed · Cited by 89
Santen, R. J., Jeng, M., Wang, J., Song, R. X.-D., Masamura, S., McPherson, R., Santner, S. J., Yue, W., & Shim, W.-S. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00151-0 · Cited by 89
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk
Healey, C. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.2.189 · Cited by 88
Dowsett, M., Stein, R. C., & Coombes, R. C. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90201-s · Cited by 81
Self-citationDeFriend, D. J., Anderson, E., Bell, J. P., Wilks, D. P., West, C., Mansel, R., & Howell, A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.281 · Cited by 78
Stephen, R. L., Shaw, L. E., Larsen, C., Corcoran, D. L., & Darbre, P. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105892200 · Cited by 67
Falkson, C. I., & Hc, F. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010634 · Cited by 66
4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer
Coombes, R. C., Hughes, S. W. M., & Dowsett, M. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90232-q · Cited by 64
Self-citationDistribution of aromatase P450 transcripts and adipose fibroblasts in the human breast
Bulun, S. E., Sharda, G., Rink, J., Sharma, S., & Simpson, E. R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772611 · Cited by 59
Analysis of the aromatase cytochrome P450 gene in human breast cancers
Sourdaine, P., Parker, M. G., Telford, J., & Miller, W. R. (1994) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0130331 · Cited by 58
Johnston, S. R. D., Boeddinghaus, I., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M. G., Grimshaw, R., Jarman, M., & Dowsett, M. (1999) · PubMed · Cited by 58
Self-citationJohnston, S. R. D., Lu, B., Dowsett, M., Liang, X., Kaufmann, M., Scott, G. K., Osborne, C. K., & Benz, C. C. (1997) · PubMed · Cited by 50
Self-citationOestrogen receptor mutants and variants in breast cancer
Dowsett, M., Daffada, A. A. I., Chan, C. M. W., & Johnston, S. R. D. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00100-7 · Cited by 49
Self-citationEffect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat
Sinha, S., Kaseta, J., Santner, S. J., Demers, L. M., Bremmer, W. J., & Santen, R. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005937900788 · Cited by 48
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Brodie, A., Jelovac, D., & Long, B. J. (2003) · PubMed · Cited by 47
No association between a single nucleotide polymorphism in CYP19 and breast cancer risk.
Haiman, C. A., Hankinson, S. E., Spiegelman, D. L., Brown, M. A., & Hunter, D. J. (2002) · PubMed · Cited by 43
Screening forESR mutations in breast and ovarian cancer patients
Andersen, T. I., Wooster, R., Laake, K., Collins, N., Warren, W., Skrede, M. L., Eeles, R., Tveit, K. M., Johnston, S. R. D., Dowsett, M., et al. (1997) · Human Mutation · Cited by 28
Self-citationTheoretical considerations for the ideal aromatase inhibitor
Dowsett, M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006088405721 · Cited by 14
Self-citation
Cited by
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
The different roles of ER subtypes in cancer biology and therapy
Thomas, C., & Gustafsson, J.-Å. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3093 · Cited by 654
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 426
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
Park, J., Euhus, D. M., & Scherer, P. E. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0030 · Cited by 348
Metadata
- Authors
- Johnston, S. R. D., & Dowsett, M.
- Venue
- Nature Reviews Cancer
- Published
- 2003-11
- Volume
- 3
- Issue
- 11
- Pages
- 821-831
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2028122342
- Cited by
- 326
- References
- 89
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.